BayesPK Generics gives portfolio, formulation, analytical, QA, manufacturing, and regulatory teams one operating layer for selecting products, designing Q1/Q2-ready formulations, controlling batch economics, preparing ANDA/eCTD evidence, and managing lifecycle obligations across India, US, EU, and tender-driven markets.
Indian manufacturers compete on speed, compliance discipline, procurement leverage, and reliable scale-up. This command view keeps the commercial and technical evidence moving together.
A disciplined path for teams that need product decisions to survive cost review, scale-up, and regulatory scrutiny.
Define QTPP, RLD expectations, dose strength, route, release goals, and evidence burden.
Generate formulation options aligned with API properties, Q1/Q2 intent, and manufacturability.
Balance material cost, dissolution behavior, process risk, and batch economics.
Connect scale-up rationale, f2 similarity, BE results, and CMC narrative into review-ready evidence.
The suite is shaped around the work Indian companies do every day: portfolio selection, API sourcing, cost pressure, plant transfer, quality documentation, regulated-market filing, and lifecycle maintenance.
Search or filter by operating lane: portfolio, CMC, analytical, manufacturing, quality, regulatory, or lifecycle. Each module opens directly into a working tool.
Generic profitability depends on repeatable commercial batches, not only a promising lab-scale formula.
The strongest generic programs treat composition, cost, scale-up, stability, pharmacovigilance, dissolution, BE, Module 3 content, eCTD package assembly, deadline tracking, and post-approval obligations as one connected evidence system.